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Objective: Information on outcome of patients with long superficial femoral artery (SFA) obstruction undergoing
endovascular treatment is scarce. The present study reports results from a prospective multicenter registry designed to
evaluate the safety, effectiveness, and patency of the aSpire self-expanding polytetrafluoroethylene covered stent (Vascular
Architects Inc, San Jose, Calif) in patients with femoropopliteal occlusive disease.
Method: The aSpire Registry included 150 patients (166 limbs) enrolled in 16 centers during a 28-month period (2003
to 2005) for medium/long (>3 cm) occlusion (n  115) or stenosis (n  51) of the SFA (n  51) or of the proximal
popliteal (n  115) arteries. Procedures were performed for intermittent claudication in 92, for rest pain in 33, and for
limb savage in 41. The mean length of arterial segment covered was 107.35  73.7 mm. Indications for treatment
included 44 type B1, 57 type B2, 47 type C1, and 18 type D lesions according to TransAtlantic Inter-Society Consensus
classification. Clinical and ultrasound evaluation was performed at discharge and at 1, 6, 12 months, and yearly
thereafter. Mean follow-up was 13 months (range, 1 to 36). Primary end points were immediate technical success (vessel
recanalization with residual stenosis <30%) and stent patency.
Results: Initial technical success was obtained in 162 (97.6%) of 166 procedures. More than one stent was applied in 48
procedures, for a total of 214 stents. No periprocedural deaths occurred. Procedure-related complications occurred in 22
of 166 procedures, including 6 peripheral embolizations, 7 thromboses, 2 hemorrhages requiring revision, 1 vessel
rupture, and 6 vessel dissections. Life-table estimates of primary patency at 12, 24, and 36 months were 64%, 59%, and
59%, respectively. Thirty-two reinterventions were performed during follow-up, resulting in secondary patency rates at
12, 24, and 36 months of 74.2%, 67%, and 67%, respectively. Amputation was required in six of 41 patients treated for
limb salvage. At multivariate analysis, critical limb ischemia was the only significant predictor of late failure.
Conclusion: Endovascular treatment of SFA occlusive lesions provides interesting results. Length of lesion and clinical
symptoms influence negatively the patency. The aSpire covered stent showed good mid-term results, but a number of
reinterventions were necessary to obtain an optimal secondary patency. Risk of patency failure was related to critical limb
ischemia as an indication for the procedure. Technologic and pharmacologic improvement and longer follow-up are
needed to define the indications for the aSpire stent. ( J Vasc Surg 2007;45:32-9.)During the last few years, the treatment of superficial
femoral artery (SFA) occlusive disease has witnessed the intro-
duction of more aggressive endovascular therapy. However,
the efficacy of femoropopliteal endovascular treatment re-
mains controversial because of inconsistent reporting stan-
dards. Cumulative patency rates of 26% to 90% over 1 to 5
years are evidence of the wide variability of the published
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32results owing to differences in vascular anatomy, clinical pre-
sentation, and criteria used to define success.1-3
Reports from the last two decades suggested that SFA
angioplasty might be an adequate short-term intervention,
although long-term patency was poor. Randomized trials
have shown that primary stenting does not add any benefit
to percutaneous transluminal angioplasty alone.4-6 In the
meantime, technology and stent design for femoropopliteal
occlusive lesions have continued to change, and the possi-
bility for treating SFA obstruction has dramatically in-
creased. Balloon-expandable stents associated with late
stent deformation and mechanical compression resulting in
late clinical failure have been replaced mainly by newer
self-expanding stents and stent grafts that have shown
improved initial results but late mechanical fatigue and
associated restenosis. The use of nickel titanium (nitinol)
offered the theoretic possibility of superior patency because
of its self-expandable form, continued radial force, and
ability for crush recovery.
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the role of newer endovascular techniques for treating SFA
obstruction, and factors that are predictive of success or
failure of these interventions remain to be defined. This
report outlines the experience of a registry designed to
evaluate safety, effectiveness, patency, and factors influenc-
ing failure of the aSpire, a self-expanding spiral nitinol stent
covered with expanded polytetrafluoroethylene (ePTFE)
(Vascular Architects Inc, San Jose, Calif), in patients with
femoropopliteal occlusive disease.
MATERIALS AND METHODS
The aSpire Registry is a multicenter prospective registry
specifically designed to assess the applicability of aSpire
stenting during a 28-month recruitment period (January
2003 to April 2005). Sixteen centers participated in the
study. The database included demographic information,
cardiovascular risk factors profile, clinical presentation,
lesion characteristics according to the Trans-Atlantic Inter-
Society Consensus classification (TASC),7 and preproce-
dure and postprocedure hemodynamics, including ankle-
brachial pressure index (ABI), operative, and follow-up
data. Patient risk factors and comorbidities, including age,
gender, smoking history, diabetes, hypertension, and end-
stage renal disease, were determined according to The
Society of Vascular Surgery reporting standards.8 The pri-
mary end point of the registry was primary and secondary
stent patency. Secondary end points were technical success,
limb salvage, and complications occurring 30 days or
during follow-up.
Inclusion criteria were SFA and/or above knee popli-
teal artery stenosis or occlusion3 cm with vessel diameter
of 5 to 10 mm, presence of critical limb ischemia (CLI)
(Rutherford stages 4 to 6) or disabling intermittent claudi-
cation (Rutherford stage 3) persisting for 6 months after
best medical treatment (including walking exercise, anti-
platelet therapy, and risk factors amendment), patient com-
pliance with treatment, and informed consent. Patients in
whom revascularization included concomitant supraingui-
nal or distal procedures were included, but patients with an
immediate need for revascularization (acute ischemia), a
functionally useless limb, or crossing knee joint lesions were
excluded. The study was performed according to the Dec-
laration of Helsinki, and the registry was approved by the
Review Boards of the Coordinating Center.
Device description. The aSpire covered stent is made
of nitinol shaped in a double spiral and fully encapsulated
with a thin layer of ePTFE, so that there is no tissue-to-
metal or metal-to-blood contact. The stent is deployed
through a delivery catheter consisting of two independent
shafts (one within the other) that can be rotated in opposite
directions to coil and uncoil the stent. When deployment is
not optimal, the stent can be recoiled, repositioned, and
re-expanded to precisely locate the stent. The final open
spiral configuration is designed to maintain compliance,
promote laminar flow, and preserve collateral vessel. For
the purpose of the registry, the stent graft was available inlengths of 50, 100, and 150 mm, with diameters of 6 to
8 mm.
Preoperative and intraoperative management. Before
the procedure, all patients underwent preoperative ultra-
sound evaluation, including ABI index measurements and
color duplex examination to visualize the extension and
morphology of the femoropopliteal lesion. Angiography
was performed before operation or directly in the operating
room during the procedure.
Routinely an anterograde puncture was used to access
the common femoral artery (CFA), except in cases of severe
obesity or lesions at the origin of SFA, where the approach
was contralateral. In cases of diffuse lesions or severe calci-
fications of CFA, a surgical approach through a small groin
incision under local anesthesia was used. For TASC type D
lesions, a debulking technique, remote superficial femoral
artery endarterectomy (RSFAE) using a ring stripper (Voll-
mar Dissector; Aesculap, South San Francisco, Calif; Mar-
tin Dissector, Vascular Architects Inc), and a ring strip
cutter (MollRingCutter, Vascular Architects Inc) was used.
After intraluminal catheterization with a 0.035-inch
hydrophilic guidewire, insertion of a 7F or 8F introducer
sheath, and performance diagnostic angiogram, intrave-
nous heparin (100 UI/kg) was administered. After recan-
alization of the SFA with balloon angioplasty, the aSpire
stent was deployed to cover all plaques compromising
luminal diameter in the area of the target vessel and then
remodeled by balloon. The balloon diameter corresponded
to the proximal undiseased vessel diameter, and stent diam-
eter was oversized 10%. Stent implantation was never
performed in the middle or distal third of the popliteal
artery. A completion angiogram concluded the procedure.
Follow-up. All patients were discharged with oral an-
tiplatelet therapy consisting of aspirin indefinitely and clo-
pidogrel (75 mg per day) or ticlopidine (250 mg twice
daily) for at least 1 month after the procedure. Anticoagu-
lant therapy was initiated in selected patients. Patency
during follow-up was evaluated with color duplex exami-
nation, including ABI measurements when assessable, at 1,
6, 12 months, and yearly thereafter. Angiography or com-
puted tomography angiography were performed when in-
dicated. The follow-up period extended from February
2003 to March 2006 (mean, 13 months; range, 1 to 36
months).
Definitions. Arterial disease extension and severity
were graded using the TASC score.7 Vessel calcification was
classified as moderate/severe (circumferential and diffuse
calcifications) or mild (not circumferential, spot calcifica-
tions). Technical success was defined as SFA recanalization
with residual stenosis 30%. Clinical success was intended
as symptom improvement and healing of necrotic lesions
when present. Primary patency was defined as a patent SFA
segment without recurrent stenosis or the need for further
intervention. Secondary patency was defined as a SFA seg-
ment with hemodynamic failure that underwent further
intervention within the inflow, the treated vessel segment,
or outflow of the treated vessel segment to improve or
restore patency. A secondary bypass graft performed after
JOURNAL OF VASCULAR SURGERY
January 200734 Lenti et alpermanent occlusion of the treated SFA was considered a
failure that allowed for tertiary patency.
Statistical analysis. Patency rates were calculated us-
ing life-table estimates. The univariate influence of dichot-
omous variables on patency was determined. The 2 test or
Fisher’s exact test was used for comparisons. The influence
of the 10 variables of male gender, smoking habit, hyper-
tension, diabetes, run-off status, length of stented artery,
symptoms, concurrent vascular procedures, target lesion
10 cm, and stenting at the above-knee popliteal artery
affecting secondary and primary patency was tested by
multivariate analysis using Cox proportional hazards re-
gression model. Statistical analysis was performed with
SPSS software (SPSS Inc, Chicago, Ill). P  .05 was con-
sidered statistically significant.
RESULTS
Patient population. The study included 150 patients
for a total of 166 limbs. Mean age was 70.4 years (range, 40
to 88 years), and 119 (79.35%) were men. Demographic
data, risk factors, and comorbidities are summarized in
Table I. There were high rates of diabetic patients (51%)
Table I. Demographic and clinical data
Characteristic N %
Male 119 71
Mean age (range) 70.4 (40-88)
Smoking 77 46.3
Diabetes 85 51.2
Hypertension 120 72.2
Coronary disease 54 32.5
End-stage renal failure 7 4.2
Cerebrovascular disease 8 4.8
Table II. Clinical category of treated limbs and anatomic
and angiographic lesion characteristics
Characteristic N %
Disabling claudication* 92 55.4
Critical limb ischemia† 74 44.6
Type of lesion
Stenosis 51 30.7
Occlusions 115 69.3
Site of lesion
Proximal SFA 51 30.7
Distal SFA/AK PA 115 69.3
Calcification
Moderate/severe 88 53
Mild/none 78 47
Run off vessels
1 67 40.3
2 70 42.1
3 29 17
Target lesion length, mean mm (range) 107 (30-450)
SFA, Superficial femoral artery; USAK PA, above-knee popliteal artery.
*Rutherford stage 3.
†Rutherford stages 4-6.and smokers (46%). Indications for treatment are reportedin Table II. Procedures were performed for claudication in
55% (n  92), and 45% (n  74) were for critical limb
ischemia, including 20% (n 33) for rest pain (Rutherford
stage 4) and 25% (n 41) for tissue loss (Rutherford stages
5 to 6).
Anatomy. The mean length of the artery target lesion
was 107.35 mm (range, 30 to 450 mm). All treated lesions
were in TASCB, C, or D groups. Specifically, there were 44
category B1 (27%), 57 category B2 (34%), 47 category C
lesions (28%), and 18 category D (11%). Type of lesions,
including calcification and run-off status, are reported in
Table II. More than one stent was applied in 48 procedures,
resulting in a total of 214 aSpire stent implants.
Immediate outcome. An antegrade percutaneous
puncture was used in 106 procedures, and in the remaining
10 cases (6%), the access was through the contralateral
femoral artery owing to the presence of lesions involving
the proximal SFA or severe patient obesity. In 50 patients
(29.4%), an ipsilateral surgical approach through a small
groin incision was performed for severe vessel calcification
or diffuse CFA disease (n  32) or when RSFAE was
required (n  18).
Operative data are summarized in Table III. No
perioperative deaths occurred. Technical and clinical
success was obtained in 162 (97.6%) of 166 procedures.
Procedure-related complications occurred in 22 proce-
dures, including 6 peripheral embolizations, 2 hemor-
rhages requiring surgical revision, 1 vessel rupture, 6
vessel dissections, and 7 intraoperative thromboses. All
complications were successfully treated at the time of the
primary procedure, with preserved stent patency except
for three persistent thromboses and one vessel rupture
Table III. Procedural data on 166 saphenofemoral
arteries with aSpire stenting
Procedure N %
Surgical approach 50 30
RSFAE 18 11
Percutaneous approach 116 70
Homolateral 106 64
Contralateral 10 6
Stented artery length, mean mm (range) 116.56 (5-300)
Fluoro time, mean min (range) 24 (7-180)
Associated procedures 44 26.5
Inflow 15 9
CFA endarterectomies 12
Proximal SFA angioplasty 3
Outflow 29 17.5
Popliteal-tibial bypass 1
Tibial trunks angioplasty 28
Procedural time (min)
60 90
60-120 47
120-180 22
180 7
Contrast media, mean mL (range) 110 (30-400)
RSFAE, Remote superficial femoral artery (SFA) endarterectomy; CFA,
common femoral artery.requiring surgical by-pass. One thrombosis, one vessel
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perforation occurred during procedures in which RSFAE
techniques were used.
Mid-term and longer-term results. Mean follow-up
was 13 months (range, 1 to 36 months). Six late deaths
occurred frommyocardial infarctions (n 4), cancer (n 1),
and cerebral hemorrhage (n 1).
During follow-up, there were 15 restenoses and 41
occlusions, of which only four occurred after the first year.
In the CLI subgroup, 24 occlusions and five restenosis
occurred. Overall, 32 reinterventions for revascularization
were performed: 16 used catheter-based techniques and 16
were with bypass surgery.
The 41 late occlusions were managed conservatively in
the case of nondisabling symptoms (n  18), or with
fibrinolysis and secondary angioplasty (n  2), bypass sur-
gery (n  15), or major amputation (n  6). All but one
restenoses (14/15) were successfully treated by balloon
angioplasty, the remaining were treated by bypass graft.
After reangioplasty, 11 arteries remained patent during the
subsequent follow-up, but three developed recurrent com-
plete occlusion. At 36 months, amputation was required in
6 (8%) of the 74 patients treated for CLI. Actuarial limb
salvage for CLI was 89.6% (Fig 1).
According to life-table estimates, primary patency rates
at 12, 24, and 36 months were 64%, 59%, and 59%,
respectively (Fig 2). Secondary patency rates at 12, 24, and
36 months were 74.2%, 67%, and 67%, respectively (Fig 3).
Secondary cumulative patency rates were significantly dif-
ferent between the subgroup of patients affected by critical
limb ischemia and those with claudication (58% vs 74%; P
Fig 1. Limb salvage in 74 superficial femoral artery aSpire stents
in patients with critical limb ischemia (CLI) by life-table analysis.
Dashed line indicates SE 10%..001; Fig 4).Risk factor analysis. Results of univariate analysis to
identify the association of periprocedural factors with pri-
mary and secondary patency are summarized in Table IV.
None of the overall 10 variables tested with multivariate
analysis was found to be a significant predictor of primary
patency. The presence of CLI (hazard ratio [HR], 2; 95%
confidence interval [CI], 1.067 to 3.957; P .03) was the
only negative predictor of secondary patency. Length of
stented artery showed a trend to negatively influence both
primary (HR, 1.005; 95% CI, 1 to 1.009; P  .04) and
secondary patency (HR, 1.006; 95%CI, 1.01 to 1.011; P
Fig 2. Primary patency by life-table analysis.Dashed line indicates
SE 10%. The number of patients at risk for each interval is
recorded.
Fig 3. Secondary patency by life-table analysis. Dashed line indi-
cates SE 10%. The number of patients at risk for each interval is
recorded..03).
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Performance and efficacy of endovascular procedures in
the treatment of SFA lesions is still controversial, and the
use of stents has not given adequate answers. The reported
1-year patency rates vary between 50% and 81%5,9,10 for
femoropopliteal non-nitinol stents and from 58% to 90%
with nitinol use.11-15 Nonetheless, intimal hyperplasia
causing stenosis, inadequate stent surface healing allowing
thrombosis, or stent fracture, or a combination of these, are
major problems. The ideal stent should provide adequate
radial force to resist external compression while avoiding a
dense metal skeleton that promotes luminal thrombosis.
Different materials, covering surfaces, and stent configura-
tions are suggested solutions to overcome these difficulties.
The aSpire stent has a unique design consisting of a
nitinol double-spiral frame covered in a thin layer of
ePTFE. The hypothesized benefits of this design are high
radial force and longitudinal flexibility that allow effective
placement in an area of excessive movement, such as in the
femoropopliteal segment. The spiral-shaped nitinol frame
was designed to ensure conformability to the vessel lumen
without occluding important collaterals. The particular
ePTFE covering provides enhanced luminal coverage com-
pared with other nitinol stents.
The aSpire Registry has proven most of these supposed
advantages and shown that stenting of the SFA using this
new type of nitinol covered spiral stent may be performed
with minimal morbidity and is associated with reasonable
patency rates in TASC B, C, and D lesions. In this multi-
center experience nitinol stents demonstrated 24-month
Fig 4. Secondary patency by clinical category. Critical limb isch-
emia (CLI) and claudicant patients determined by life-table anal-
ysis. Dashed line indicates SE 10%. The difference between
groups was significant (P  0.01, log-rank test). The number of
patients at risk for each interval is recorded.primary patency and secondary patency rates of 59% and67%, respectively. Limb salvage rates in patients with CLI
were also good (89.6%), in part as a result of the spared
collateral flow depending on the spiral shape of the aSpire
being able to ensure viability of the limb in case of acute
occlusion. Indeed, no secondary intervention was per-
formed in 18 of our late occlusions because there was no
recurrence of disabling symptoms. Only six amputations
were required in patients with history of stage 5 to 6 CLI.
The results of SFA stenting were, however, highly depen-
dent on the clinical presentation; the presence of CLI was
associated with lesser patency with respect to claudicant
patients (58% vs 74%, respectively, P  .01). Multivariate
analysis confirmed CLI as the only significant factor affect-
ing secondary patency (HR, 2; 95% CI, 1.067 to 3.957; P
 .03).
Our data indicate the presence of CLI might signal
caution when challenging SFA stenting procedures are
attempted. On the other hand, it is well known that lower
extremity ischemia is a marker for cardiovascular mortality,
and treatment is associated with substantial morbidity,
mortality, and expenditure of health care resources. Al-
though bypass grafting with 5-year limb salvage rates of
80% is still considered by most vascular surgeons the gold
standard of treatment for most infrainguinal lesions, sys-
temic and local complications may occur in up to 25% of
patients, and the associated morbidity may compromise
functional outcomes, as 50% of patients report a return to
normal functional status by 6 months.16-19 In this regard,
the good limb salvage rate for patient with CLI and tissue
loss may let us consider the aSpire stent as an option for
patients with CLI at high surgical risk, even if patency rates
may be reduced during time.
Despite material characteristics that were suggested to
play a role in maintaining patency in femoropopliteal le-
sions, the aSpire Registry showed that a number of catheter-
based secondary procedures (n  16) were needed to
preserve good secondary patency during follow-up. How-
ever, 14 of the 15 restenoses that caused failure were
amenable to additional percutaneous interventions, with
minimal morbidity and durable results: 78% were still
patent at 36 months.
Although failure after stenting may be related to pro-
gression of disease in the inflow and outflow vessels,1 our
data support the hypothesis that intimal hyperplasia is still a
problem affecting mid-term results of nitinol stent for long
SFA obstruction (10 cm). Indeed, most of our failures
occurred within the period of intimal hyperplasia response
(52/56 12 months, Figs 2 and 3). In any case, the
number of failures after the first year was relatively low,
suggesting a protective role of the stent favoring the heal-
ing of the treated segment. In fact, the cumulative sec-
ondary patency rate of 67% at 24 months is good if we
consider the frequency of CLI, the multilevel occlusive
vascular disease, the mean length of lesion, and TASC C
and D prevalence. Larger studies with longer follow-up are
needed to confirm the hypothesized long-term advantage
of the aSpire stent.
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severity of preoperative symptoms. Occlusion rates were
found about twofold more frequently in the subgroup of
74 patients with CLI with respect to the 92 with claudica-
tion (18% vs 32%), while the reverse occurred for restenosis
rates (11% vs 6.7%, respectively). Although there were no
significant differences in primary patency rates between
patients with claudication and CLI, secondary patency rates
were significantly better for those with claudication (Fig 4).
It could be hypothesized that most of the failures occurring
in the claudicant patients may be caused by intimal hyper-
plasia leading to restenosis without occlusion that is easily
and successfully manageable with redo treatment. On the
other hand, patients with CLI presented with unviable
occlusions (24 of 29 overall failures in this group), likely
due to more aggressive, extensive vascular disease and the
coexistence of multiple adverse factors such as poor run-off
status, diabetes, and others.
In this regard, multiple factors have been shown to
adversely affect patency rates of the treated artery, such as
type (stenosis vs occlusion) and length of target lesion,
distal runoff, and presence of diabetes or end-stage renal
disease.19-22 In the present study, regression analysis
showed that above-knee involvement, target lesion length,
and run-off status did not predict stent failure in SFA,
although the total number of limbs treated per category
was quite small. The same applies for diabetic and end-stage
renal patients. Given our study population of 85 diabetic
and seven end-stage renal patients, it is possible that such a
conclusion may represent a type II error. Larger studies will
likely allow firmer conclusions about the appropriateness of
treating these lesions in patients as first-line endoluminal
treatment.
The length of the stented artery more than the target
lesion showed a tendency to negatively influence patency in
the aSpire Registry, although the HR close to 1 at the
multivariate analysis did not allow a relevant association
(HR, 1.006; 95% CI, 1.001 to 1.011; P  .03). The length
Table IV. Univariate analysis of factors associated with pr
Primary pa
Yes (n  110) No (n
n (%) n
Male gender 80 (72) 39
Smoking habit 49 (44) 28
Hypertension 85 (77) 35
Diabetes 57 (51) 28
Run-off status* 46 (41) 21
End-stage renal disease 3 (2.7) 4
Moderate/severe calcification 61 (55) 27
CLI 45 (41) 29
AK popliteal site of lesion 76 (69) 40
Inflow/outflow procedures 39 (35) 16
Length of target lesion (10 cm) 46 (42) 23
CLI, Critical limb ischemia; AK, above-knee.
*Run-off status: 2 run-off vessels.of the covered artery is probably a marker of technicaldifficulties and procedure complexity, because arterial dis-
section or rupture or unexpected lesions require longer
stent coverage. Indeed, when we observe our patency
curves (Figs 2 and 3), most of the failures occurred early,
within the first 12 months, reflecting that in addition to
intimal hyperplasia, a potential adjunctive negative effect
on the outcome might be the consequence of a procedural
challenging technique.
Optimal ballooning predilation more than postdilation
is a key factor to obtain good technical success. Poor
predilation may cause under-expansion of the stent and
residual stenosis. Conversely, excessive ballooning after
deploymentmay be dangerous, because this leads to arterial
trauma, promotes intimal hyperplasia, and perhaps, favors
stent restenosis. Postdilation limited in pressure and lo-
cated within the confines of the stent to allow a controlled
dissection plane is recommended. Similarly, unnecessary
stent diameter oversizing (10%) is to be avoided.
Perhaps a partial or complete debulking of the native
vessel by removal of the atherosclerotic core rather than
reshaping the lumen of a long arterial occlusion by angio-
plasty/stenting may reduce the restenosis coming from
intimal hyperplasia. The hypothesis of complete SFA de-
bulking in a remote SFA endarterectomy technique is
appealing although not yet supported by convincing
data.23-26 Rosenthal et al23 and Knight et al,24 using
remote endarterectomy with an aSpire stent in long SFA
occlusions, reported an assisted primary patency rate of
88.6% at 18 months. More recently, Martin et al25 reported
primary patency rates of 70% and limb salvage rates of 94%
at 30 months for 105 SFA remote endarterectomies.
Similar better mid-term outcome was confirmed in our
limited subgroup of 18 procedures where RSFAE tech-
nique was employed: primary patency was 67% at a mean
follow-up of 9 months (range, 6 to 12 months). With a
larger experience, a decrease in complication rates with this
demanding procedure is to be expected.
Newer competitive treatment strategies combined with
y and secondary patency
Secondary patency
6)
P
Yes (n  126) No (n  40)
Pn (%) n (%)
1 90 (71) 29 (72) 1
0.4 54 (43) 23 (57) 0.2
0.1 94 (75) 26 (65) 0.1
1 62 (49) 23 (57) 0.48
0.87 51 (40) 16 (40) 1
0.22 5 (4) 2 (5) 1
0.62 68 (54) 20 (50) 0.59
0.24 50 (40) 24 (60) 0.047
0.47 86 (68) 30 (75) 0.7
0.6 43 (34) 12 (30) 0.57
0.87 52 (41) 17 (42) 1imar
tency
 5
(%)
(70)
(50)
(62)
(50)
(37)
(7)
(48)
(52)
(71)
(28)
(41)pharmacologic means of preventing the intimal hyperplas-
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improve the durability of endovascular treatment for long
femoropopliteal lesions. Drug-eluting stents and cryoplasty
have been introduced, but there is no evidence of clear
benefit, as no comparative studies or long-term data are
available. The final results of the cryovascular safety registry
reported a primary patency rate of 82% in 102 patients at 10
months.27 Duda et al28 performed a randomized trial com-
paring the use of sirolimus-eluting shape-memory alloy
recoverable technology (SMART) nitinol stents vs un-
coated SMART nitinol stents in 36 patients with CLI and
femoral artery stenosis or occlusion. At 6 months, the
in-stent mean lumen diameter was 4.31 mm in the un-
coated stent group vs 4.95 mm in the sirolimus group. No
significant differences in patency or limb salvage were
found in this study.28,29
Other techniques, such as subintimal angioplasty and
excimer laser, that may ultimately be good alternative tech-
niques to stents in long SFA occlusion (TASC C and D) are
all still providing conflicting or disappointing results.30-33
Study limitations. This report does not address the
assessment of patient satisfaction or the comparative appli-
cation of surgical bypass grafting vs stenting. Stenting was
used when anatomically feasible. However, studies on pa-
tients after surgery have shown up to 20% patients are
dissatisfied with surgical outcome, even with an improved
and normal postoperative ABI.34,35
Another limitation of this study is the limited number
of patients who achieved the longest follow-up. Since the
longer the follow-up, the greater the number of SFA stent
failures there might be, aSpire patency rates could deterio-
rate when a larger number of stented patients are observed
for a longer interval. Further studies are needed to confirm
the good surface healing endorsed by aSpire stenting in a
period 36 months.
Cost assessment was not a focal point of this analysis.
With the present report we could not assess true efficacy
of aSpire stenting in SFA obstructive disease, as only ran-
domized studies can ascertain, but we would like to provide
an image of the common drawbacks and advantages in the
use of this type of stent. The availability of the registry
helped to obtain information from different centers and
different patient populations, increasing the generalization
of the results.
CONCLUSIONS
The decision to proceed with angioplasty and stenting
to treat SFA occlusion, particularly for TASC C and D
lesions, is challenging. Reasons usually include the prefer-
ence of the patient or physician for minimally invasive
treatment, the fact that surgery can usually proceed after
the failure of endoluminal intervention, short-term tissue
healing goals, patients at too high risk for open surgical
procedure,or infectionat theproposedsurgical site.Quality-
of-life issues need to be taken into account when treatment
options are discussed with patients. This study suggests that
SFA aSpire stenting is a reasonable and safe procedure with
good patency and limb salvage rates. Clinical presentationmay negatively affect the outcome, 24 months secondary
patency rates being worse for patients with CLI: 58% vs
74% for claudication. However, limb salvage may be en-
sured in up to 90% of patients with CLI. Technologic and
pharmacologic improvement, together with longer follow-
up, are needed to define the indications for the aSpire stent.
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